AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA approved Lokelma sodium zirconium cyclosilicate (ZS-9) to treat hyperkalemia in adults. AZ had received two CRLs for Lokelma following manufacturing concerns (see BioCentury Extra, March 17, 2017).
{iframe}https://www.biocentury.com/bc-extra/company-news/2018-05-18/third-time%E2%80%99s-charm-az-hyperkalemia-drug{/iframe}